Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells by Hong, Tae Ho et al.
1
Vol.:(0123456789)
Scientific Reports |          (2021) 11:874  | https://doi.org/10.1038/s41598-020-79536-z
www.nature.com/scientificreports
Application of self‑assembly 
peptides targeting 
the mitochondria as a novel 
treatment for sorafenib‑resistant 
hepatocellular carcinoma cells
Tae Ho Hong1,2, M. T. Jeena3, Ok‑Hee Kim1,2, Kee‑Hwan Kim2,4, Ho Joong Choi1,2, 
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Currently, there is no appropriate treatment option for patients with sorafenib‑resistant 
hepatocellular carcinoma (HCC). Meanwhile, pronounced anticancer activities of newly‑developed 
mitochondria‑accumulating self‑assembly peptides (Mito‑FF) have been demonstrated. This 
study intended to determine the anticancer effects of Mito‑FF against sorafenib‑resistant Huh7 
(Huh7‑R) cells. Compared to sorafenib, Mito‑FF led to the generation of relatively higher amounts 
of mitochondrial reactive oxygen species (ROS) as well as the greater reduction in the expression 
of antioxidant enzymes (P < 0.05). Mito‑FF was found to significantly promote cell apoptosis while 
inhibiting cell proliferation of Huh7‑R cells. Mito‑FF also reduces the expression of antioxidant 
enzymes while significantly increasing mitochondrial ROS in Huh7‑R cells. The pro‑apoptotic effect 
of Mito‑FFs for Huh7‑R cells is possibly caused by their up‑regulation of mitochondrial ROS, which is 
caused by the destruction of the mitochondria of HCC cells.
Abbreviations
GPx  Glutathione peroxidase
Huh7-S cell  Sorafenib-sensitive Huh7 cell
Huh7-R cell  Sorafenib-resistant Huh7 cell
Mito-FF  Mitochondria-accumulating phenylalanine dipeptide with triphenyl phosphonium
p-ERK  Phosphorylated extracellular signal-regulated kinase
SOD  Superoxide dismutase
BAX  Bcl-2-like protein 4
Bcl-xL  B-cell leukemia-extra large
c-Cas3  Cleaved caspase-3
c-Cas9  Cleaved caspase-9
PARP  Poly-ADP (adenosine diphosphate)-ribose polymerase
NAC  N-Acetyl-l-cysteine
ROS  Reactive oxygen species
Hepatocellular carcinoma (HCC) has very poor prognosis due to the usual detection at the advanced stages of 
the disease, the presence of underlying cirrhosis, and paucity of effective treatments. Although various chemo-
therapeutic agents have been applied for the treatment of advanced HCC, none was able to prolong survival 
until the mid-2000s. Subsequently, sorafenib has demonstrated significant improvement in survival compared to 
placebo in phase 3 clinical studies in advanced HCC  patients1. Sorafenib is a tyrosine kinase inhibitor that was 
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approved by the United States Food and Drug Administration (FDA) in 2007 as the first-line systemic therapy for 
 HCC2,3. Sorafenib acts on a variety of sites, including vascular endothelial growth factor receptor 1 (VEGFR1), 
VEGFR2, VEGFR3, platelet-derived growth factor receptor beta (PDGFR-β), and RAF-family  kinases4. In the 
SHARP phase 3 trial incorporating 602 HCC patients, sorafenib improved mean overall survival by approximately 
2–3 months compared to the placebo group (10.7 vs. 7.9 months; P < 0.001)1,5. However, sorafenib frequently 
causes side effects, including diarrhea, hand-foot syndrome, and fatigue, which results in poor patient compli-
ance. The most common reasons for discontinuation of sorafenib are gastrointestinal events (6%), fatigue (5%), 
and liver dysfunction (5%)1. Moreover, resistance to sorafenib is very prevalent; in the SHARP trial, one-quarter 
of patients experienced  resistance1,5. Presently, there is no appropriate treatment option for the patients with 
sorafenib-resistant  HCC6–9. These limitations with sorafenib have compelled the need to develop novel or sup-
plementary drugs for patients that are adversely affected by sorafenib.
We previously validated the pronounced anticancer properties of a newly developed mitochondria-accumulat-
ing phenylalanine dipeptide with triphenyl phosphonium (Mito-FF)10,11. Mito-FF accumulates in mitochondria 
at concentrations that are 500–1000 times higher concentration than that of other spaces, making self-assembly 
possible by allowing the concentration of Mito-FF to exceed critical aggregation concentration (CAC)11,12. Mito-
FF consists of diphenylalanine, TPP, and pyrene, Diphenylalanine peptides are essential building blocks that also 
make up amyloids in Alzheimer’s disease and other neurodegenerative diseases. Assembled diphenylalanine 
peptides form β-sheets, supported by hydrogen bonding and π–π stacking of aromatic  residues13,14. TPP is a 
delocalized lipophilic cation that is crucial in the accumulation of Mito-FF in the mitochondria. Since the mito-
chondrial inner membrane has a negative potential, the positively charged TPP can facilitate the accumulation of 
Mito-FF in the mitochondrial matrix to levels that exceed the CAC and drive self-assembly. Final constituent of 
Mito-FF is pyrene that acts as a florescent probe. This study was undertaken to determine the anticancer effects 
of Mito-FF against sorafenib-resistant HCC cells. If Mito-FF is demonstrated to have significant anticancer 
effects on sorafenib-resistant HCC cells, it is expected to provide new possibilities for the treatment of patients 
with sorafenib-resistant HCC.
Results
Generation of sorafenib‑resistant HCC cells. Mito-FF is a type of self-assembly peptide that targets 
mitochondria, and consists of diphenylalanine, TPP, and pyrene (a fluorophore) (Fig. 1A). Mito-FFs are expected 
to be accumulated in the mitochondrial matrix after passing the mitochondrial inner membrane, wherein they 
are self-assembled to form a fibrous structure, eventually leading to apoptotic cell death by destructing mito-
chondria in tumor cells.
To generate sorafenib-resistant strains, Huh7 HCC cells were grown in vitro at increasing doses of sorafenib 
for a total of 8 months, starting at a sorafenib concentration of 0.5 µmol/L and increasing up to 15 µmol/L. 
The sorafenib-resistant Huh7 (Huh7-R) cells were able to survive up to the concentration of 15 μM sorafenib 
(Fig. 1B). Colony assay was performed for the determination of cell survival following the administration of 
different concentrations of sorafenib and Mito-FF, respectively. When sorafenib (5–10 μM) was administered, 
sorafenib-sensitive Huh7 (Huh7-S) cells hardly formed colonies above 10 μM sorafenib. However, when Mito-FF 
(10–25 μM) was administered, no significant difference was found in the colony formation between Huh7-S/R 
cells (Fig. 1C). Following administration of Mito-FF, cell morphology was changed rapidly at 25 μM Mito-FF in 
both Huh7-S/R cells, and apoptosis is rapidly induced at 50 μM Mito-FF. We thus think that 50 μM Mito-FF is 
the optimal concentration for inducing cell apoptosis in both Huh7-S/R cells. Subsequently, western blot analysis 
was complemented to compare the expression of p53, cell proliferation-related proteins (p-AKT and p-ERK) 
and antioxidant proteins (SOD, GPx, and catalase) in each type of HCC cells (Fig. 1D). Huh7-R cells showed 
significantly lower expression of p53, p-AKT and p-ERK than Huh7-S cells (P < 0.05). Of antioxidant proteins, 
GPx was expressed higher in Huh7-R cells than in Huh7-S cells (P < 0.05).
Figure 1.  Generation and initial validation of sorafenib-resistant Huh7 cells. (A) Structure and mechanism of 
mitochondria-accumulating phenylalanine dipeptide with triphenyl phosphonium (Mito-FF). Mito-FF consists 
of diphenylalanine, triphenylphosphonium (TPP), and pyrene (a fluorophore), which serve as β-sheet-forming 
building blocks, mitochondrial targeting moieties, and fluorescent probes, respectively. Mito-FFs are expected 
to be accumulated in the mitochondrial matrix after passing the mitochondrial inner membrane, wherein 
they are self-assembled to form a fibrous structure, eventually leading to apoptotic cell death by destructing 
mitochondria in tumor cells. (B) Microphotographs showing Huh7 cells with no sorafenib [Left] and 15 μM 
sorafenib treatment [Right], respectively. Huh7 cells that can survive above 15 μM sorafenib were determined as 
Huh7-R cells. (C) Colony assay for the determination of cell survival following the administration of different 
concentrations of sorafenib and Mito-FF, respectively. (D) Western blot analysis [Left] for the comparison 
of p53, cell proliferation-related proteins (p-AKT and p-ERK) and antioxidant proteins (SOD, GPx, and 
catalase) in each type of HCC cells. [Right] Relative densities of the markers in each group. Relative densities 
of individual markers had been quantified using Image J software (http://image j.nih.gov/ij/downl oad.html ) 
and then were normalized to that of β-actin in each group. Values are presented as mean ± standard deviation 
of three independent experiments. *P < 0.05. Abbreviations: GPx, glutathione peroxidase; Huh7-S cell; 
sorafenib-sensitive Huh7 cell; Huh7-R cell; sorafenib-resistant Huh7 cell; Mito-FF; mitochondria-accumulating 
phenylalanine dipeptide with triphenyl phosphonium; p-ERK, phosphorylated extracellular signal-regulated 
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Effects of Mito‑FF on the viability of sorafenib‑resistant Huh7 cells. Cell viability test was per-
formed for the determination of the effects of sorafenib and Mito-FF on the viability of Huh7-S/R cells, respec-
tively. After sorafenib treatment, viability of Huh7-S cells decreased in concentration- and time-dependent 
manners (Fig. 2A). However, the viability of Huh7-R cells did not decrease until they were treated with high 
concentrations (≥ 15 μM). By contrast, the treatment of Mito-FF resulted in the significant reduction of cell 
viability, irrespective of sorafenib sensitivity, in concentration- and time-dependent manners (P < 0.05) (Fig. 2B).
Effects of Mito‑FF on the expression of apoptosis‑related and proliferation‑related pro‑
teins. Western blot analysis determined the expression of proteins related with apoptosis (PARP, cleaved cas-
pase-3, cleaved caspase-9, and Bcl-xL) and proliferation (p-ERK) in each type of HCC cells following sorafenib 
treatment. Overall, the expression of individual markers was similar between Huh7-S and Huh7-R cells after 
sorafenib treatment except for the expression of PARP and p-ERK. Although sorafenib generally reduced the 
expression of pro-apoptotic proteins dose-dependently, the expression of PARP in Huh7-S cells was increased 
since sorafenib was given more than 2.5 μM. On the other hand, in Huh7-R cells, the expression of p-ERK was 
increased despite increasing sorafenib concentration (Fig. 3A).
Subsequently, the expression of these markers was determined following Mito-FF treatment. Overall, the pat-
terns of expression of these markers did not show significant difference between Huh7-S/R cells. More specifically, 
the expression of pro-apoptotic markers increased to a certain concentration in a dose-dependent manner, while 
the expression of anti-apoptotic markers decreased dose-dependently. In addition, the expression of p-ERK was 
also reduced in a dose -dependent manner. Taken altogether, Mito-FF seems to promote cell apoptosis while 
inhibiting cell proliferation of Huh7 cells, regardless of whether they are Huh7-S or Huh7-R cells (Fig. 3B).
Effects of Mito‑FF on the apoptotic cell death. Cell apoptosis was further determined by flow cytom-
etry of AnnexinV/PI stained cells of each type (Supplementary Information). Sorafenib dose-dependently ele-
vated the population of Annexin V-positive cells (early and late apoptotic cells) of both cell types of Huh7 cells. 
When comparing with Huh7-S/R cells, Huh7-R cells had significantly lower apoptotic cell populations than 
Huh7-S cells at the same concentration of sorafenib (P < 0.05) (Fig. 4A). Similar to sorafenib, Mito-FF dose-
dependently elevated the population of Annexin V-positive cells of both Huh7-S/R cells (Fig. 4B). Especially, 
Figure 2.  Effects of Mito-FF on the viability of sorafenib-resistant Huh7 cells. (A) Cell viability assay of 
sorafenib-sensitive [Left]/resistant [Right] Huh7 cells following sorafenib treatment. (B) Cell viability assay 
of sorafenib-sensitive [Left]/resistant [Right] Huh7 cells following Mito-FF treatment. Values are presented as 
mean ± standard deviation of three independent experiments. *P < 0.05. Abbreviation: Huh7-S cell; sorafenib-
sensitive Huh7 cell; Huh7-R cell; sorafenib-resistant Huh7 cell; Mito-FF; mitochondria-accumulating 
phenylalanine dipeptide with triphenyl phosphonium.
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Figure 3.  Effects of Mito-FF on the expression of apoptosis-related and proliferation-related proteins. (A) (Top) 
Western blot analysis showing the expression of proteins related with apoptosis and proliferation of sorafenib-sensitive 
[Left] /resistant [Right] Huh7 cells after sorafenib treatment. (Bottom) Relative densities of the markers in each 
group. (B) (Top) Western blot analysis showing the expression of proteins related with apoptosis and proliferation 
of sorafenib-sensitive [Left]/resistant [Right] Huh7 cells after Mito-FF treatment. (Bottom) Relative densities of the 
markers in each group. Relative densities of individual markers had been quantified using Image J software (http://
image j.nih.gov/ij/downl oad.html) and then were normalized to that of β-actin in each group. Values are presented 
as mean ± standard deviation of three independent experiments. *P < 0.05. Abbreviations: BAX, Bcl-2-like protein 
4; Bcl-xL, B-cell leukemia-extra large; c-Cas3, cleaved caspase-3; c-Cas9, cleaved caspase-9; Huh7-S cell; sorafenib-
sensitive Huh7 cell; Huh7-R cell; sorafenib-resistant Huh7 cell; Mito-FF; mitochondria-accumulating phenylalanine 
dipeptide with triphenyl phosphonium; PARP, poly-ADP (adenosine diphosphate)-ribose polymerase; p-ERK, 
phosphorylated extracellular signal-regulated kinase.
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Figure 4.  Effects of Mito-FF on the apoptotic cell death. (A) Quantification of flow cytometric analysis 
of sorafenib-sensitive/resistant Huh7 cells after AnnexinV/PI staining following sorafenib treatment. The 
proportion of apoptosis cells (%) were expressed as the total percentage of Annexin V-positive/PI-negative cells. 
(B) Quantification of flow cytometric analysis of sorafenib-sensitive/resistant Huh7 cells after AnnexinV/PI 
staining following Mito-FF treatment. (C) TUNEL assay to determine apoptosis of sorafenib-sensitive [left] /
resistant [right] Huh7 cells by sorafenib, respectively. Compared to Huh7-S cells, fewer TUNEL-positive cells 
were found in Huh7-R cells after treatment with 10 μM sorafenib. (D) TUNEL assay to determine apoptosis 
of sorafenib-sensitive [left] /resistant [right] Huh7 cells by Mito-FF, respectively. Similar number of TUNEL-
positive cells were found in Huh7-R cells as well as Huh7-S cells after treatment with 25 μM Mito-FF. Values are 
presented as mean ± standard deviation of three independent experiments. *P < 0.05. Abbreviations: Huh7-S cell; 
sorafenib-sensitive Huh7 cell; Huh7-R cell; sorafenib-resistant Huh7 cell; Mito-FF; mitochondria-accumulating 
phenylalanine dipeptide with triphenyl phosphonium.
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contrasted by sorafenib treatment, there showed no significant difference in the populations of apoptotic cell 
fraction according to Huh7-S/R cells following higher concentrations of Mito-FF (50 μM), suggestive of higher 
induction of apoptotic cell death in Huh7-R cells by Mito-FF.
Subsequently, terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay were per-
formed to ascertain the induction of apoptosis in Huh7-S/R cells by sorafenib and Mito-FF, respectively. Com-
pared to Huh7-S cells, fewer TUNEL-positive cells were found in Huh7-R cells after treatment with 10 μM 
sorafenib (Fig. 4C). By contrast, similar number of TUNEL-positive cells was found in Huh7-R cells as well as 
Huh7-S cells after treatment with 25 μM Mito-FF (Fig. 4D).
Effects of Mito‑FF on the expression of antioxidant enzymes. Next, the expression of antioxidant 
proteins was investigated in each type of Huh7 cells following each treatment. Sorafenib reduced the expression 
of antioxidant proteins (SOD, GPx, and catalase) in a dose-dependent manner. When comparing with Huh7-S/R 
cells, Huh7-R cells required the higher concentration of sorafenib to reduce the expression of these antioxidant 
Figure 5.  Effects of Mito-FF on the expression of antioxidant proteins. (A) (Top) Western blot analysis showing 
the expression of antioxidant proteins of sorafenib-sensitive [Left] /resistant [Right] Huh7 cells after sorafenib 
treatment. (Bottom) Relative densities of the markers in each group. (B) (Top) Western blot analysis showing 
the expression of antioxidant proteins of sorafenib-sensitive [Left] /resistant [Right] Huh7 cells after Mito-FF 
treatment. (Bottom) Relative densities of the markers in each group. Relative densities of individual markers 
had been quantified using Image J software (http://image j.nih.gov/ij/downl oad.html) and then were normalized 
to that of β-actin in each group. Values are presented as mean ± standard deviation of three independent 
experiments. *P < 0.05. Abbreviations: GPx, glutathione peroxidase; Huh7-S cell; sorafenib-sensitive Huh7 cell; 
Huh7-R cell; sorafenib-resistant Huh7 cell; Mito-FF; mitochondria-accumulating phenylalanine dipeptide with 
triphenyl phosphonium; SOD, superoxide dismutase.
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proteins (P < 0.05) (Fig. 5A). Likewise, Mito-FF reduced the expression of antioxidant proteins of Huh7-S/R cells 
in a dose-dependent manner. However, there was no significant difference in the expression of these proteins 
between Huh7-S/R cells (Fig. 5B).
Effects of Mito‑FF on the mitochondrial ROS levels. MitoSOX Red reagent (a mitochondrial reac-
tive oxygen species [ROS] indicator) is oxidized in the mitochondria by superoxide, resulting in producing red 
 fluorescence15. Thus, mitochondrial ROS levels in the targeted cells can be determined by flow cytometric analy-
sis of the MitoSOX stained cells (Supplementary Information). MitoSOX-based flow cytometry demonstrated 
that sorafenib increased the mitochondrial ROS levels of each type of HCCs in a dose-dependent manner. When 
comparing with Huh7-S/R cells, Huh7-R cells displayed less mitochondrial ROS than Huh7-S cells (P < 0.05), 
especially at higher concentrations of sorafenib (≥ 5 μM) (Fig. 6A). Likewise, Mito-FF increased the mitochon-
drial ROS levels of each type of HCCs in a dose-dependent manner. When comparing Huh7-S/R cells, Huh7-R 
cells displayed lower levels of mitochondrial ROS than Huh7-S cells (P < 0.05), especially at higher concentra-
tions of Mito-FF (≥ 25 μM) (Fig. 6B).
Subsequently, we performed JC-1 assay to determine the alternations of mitochondrial membrane potential 
(MMP) following each treatment. In the normal cells, JC-1 fluorescent dyes accumulate in the matrix of mito-
chondria, producing red fluorescence. However, when MMP is reduced—for instant, as a result of the induction 
of apoptosis, JC-1 cannot gather the matrix so that JC-1 exists in the matrix as a monomer, producing green 
fluorescence. Sorafenib treatment to Huh7-S cells led to some of JC-1 fluorescence color change from red to green 
along with the increasing concentration of sorafenib, suggesting that MMP declined along with the increasing 
concentration of sorafenib; sorafenib treatment to Huh7-R cells did not (Fig. 6C). In addition, Mito-FF treatment 
to both Huh7-S/R cells led to the color change from red to green—to some extent—with the increasing concentra-
tion of Mitro-FF, suggesting that MMP declined along with the increasing concentration of Mito-FF (Fig. 6D).
Determination of the action mechanism of Mito‑FF in relation with ROS. The mechanism of 
action of Mito-FF on the Huh7-R cells was investigated in relation with mitochondrial ROS. Firstly, cell viability 
assay of Mito-FF treated Huh7-R cells after treating either with or N-acetyl-l-cysteine (NAC; an ROS inhibitor) 
or Z-VAD-fmk (a caspase inhibitor) was performed. Addition of NAC with Mito-FF-treated Huh7-R cells sig-
nificantly increased the cell viability (P < 0.05); addition of Z-VAD-fmk did not. These results suggest that Mito-
FF decreases cell viability of HCC cells by increasing ROS caspase-independently (Fig. 7A). Next, the expression 
of PARP (an apoptotic marker) in Huh7-R cells treated either with NAC or Z-VAD-fmk was determined by 
Western blot analysis. The addition of NAC significantly reduced the expression of PARP in the Mito-FF treated 
Huh7-R cells (P < 0.05); the addition of Z-VAD-fmk did not (Fig. 7B). These results suggest that Mito-FF also 
promotes the apoptosis of Huh7-R cells by increasing mitochondrial ROS. Subsequent MitoSOX (Fig. 7C) and 
DCF-DA (Fig. 7D) immunofluorescences support the pivotal role of mitochondrial and intracellular ROS in the 
mechanism of Mito-FF, respectively. Specifically, it was found that addition of NAC to Mito-FF-treated Huh7-R 
cells significantly reduced the levels of mitochondrial and intracellular ROS, respectively (P < 0.05); addition of 
Z-VAD-fmk did not.
Next, in order to investigate the role of p53 in the mechanism of Mito-FF, the expression of p53 according 
to each treatment was determined by immunofluorescence. Addition of sorafenib to Huh7-S cells significantly 
increased the percentage of cells with positive nuclear staining for p53; addition of sorafenib to Huh7-R cells 
did not (Fig. 8A). However, following Mito-FF treatment, there was an increase in the percentage of cells with 
positive nuclear staining for p53—regardless of Huh7-S or Huh7-R cells (Fig. 8B).
Taken altogether, the mechanism of Mito-FF can be postulated as follows (Fig. 8C). Sorafenib treatment could 
decrease AKT/ERK in Huh7-S cells and thus increases the expression of p53, favoring apoptosis. By contrast, 
sorafenib treatment could not increase apoptosis in Huh7-R cells—because they has the higher expression of 
AKT/ERK that inactivates p53. On the other hand, treating Mito-FF to Huh7-S/R cells, could substantially 
increase mitochondrial ROS, by evoking mitochondrial dysfunction due to the accumulation and self-assembly 
in the mitochondrial matrix, and thereby could increase the expression of p53, ultimately resulting in enhanced 
apoptosis, regardless of Huh7-S or Huh7-R cells.
Discussion
Sorafenib is the only globally available, molecularly targeted drug for the treatment of advanced  HCC16,17. How-
ever, its use is hindered by very limited effectiveness, higher side effects, and a broader population of resistance. 
In this study, we investigated the therapeutic effect of the novel anticancer drug—Mito-FF—in sorafenib-resistant 
HCC cells. Mito-FF is one of self-assembly peptide targeting mitochondria. Previous investigations validated 
that Mito-FFs accumulate in mitochondrial matrix, wherein they are self-assembled, evoking mitochondrial 
 dysfunction10,11,18. This is the first validation of anticancer effect of Mito-FF in the HCC cells. Regardless of 
sorafenib resistance, treatment with Mito-FF significantly reduced cell viability of Huh7 cells; significantly inhib-
ited the proliferation of Huh7 cells; and significantly increased the proportion of apoptotic cells of Huh7 cells.
In recent decades, nanoscience has progressed to become a relevant therapeutic approach. In 2005, the FDA 
approved the abraxane as a nanomedicine for metastatic breast cancer, advanced non-small cell lung cancer, and 
metastatic pancreatic  cancer19. The therapeutic applications of nanostructural assembles of amphiphilic peptides 
have also been explored as  nanomedicines19–24. Molecular self-assembly is the process by which materials—espe-
cially, peptides—combine to form ordered structures under specific kinetic and thermodynamic  conditions25–27. 
This can occur physiologically and pathologically. Physiologic examples of molecular self-assembly include the 
assembly of phospholipid biological membranes, the association of protein microtubules and microfilaments 
to provide cellular support, and the formation of the DNA double helix through hydrogen  bonding14,28. In 
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Figure 6.  Anticancer effects of Mito-FF in relation with oxidative stress. (A) Quantification of mitochondrial ROS levels of Huh7 
cells according to the increasing concentration of sorafenib by flow cytometric analysis. Mitochondrial ROS was determined by 
quantification of the red fluorescence that emits when MitoSOX Red reagent (a mitochondrial superoxide indicator) is oxidized 
by superoxide in the mitochondria. (B) Quantification of mitochondrial ROS levels of Huh7 cells according to the increasing 
concentration of Mito-FF by flow cytometric analysis. (C) [Top] Determination of mitochondrial membrane potential (MMP) using 
JC-1 dye in Huh7 S/R cells following sorafenib treatment. In normal cells, JC-1 fluorescent dyes can accumulate in the matrix of 
mitochondria, producing red fluorescence. However, when the MMP declined, JC-1 cannot gather in the matrix so that JC-1 exist in 
the matrix as monomer, producing green fluorescence. [Bottom] The ratio of the red (OD1) and green (OD2) optical density. As the 
concentration of sorafenib increased, the ratio in the Huh7-S cells declined; the ratio in the Huh7-R cells was unchanged. (D) [Top] 
Determination of MMP using JC-1 dye in Huh7 S/R cells following Mito-FF treatment. [Bottom] The ratio of the red and green optical 
density. As the concentration of Mito-FF increased, the ratios declined in both Huh7-S/R cells. Values are presented as mean ± standard 
deviation of three independent experiments. *P < 0.05. Abbreviation: Huh7-S cell; sorafenib-sensitive Huh7 cell; Huh7-R cell; 
sorafenib-resistant Huh7 cell; Mito-FF; mitochondria-accumulating phenylalanine dipeptide with triphenyl phosphonium.
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addition, the representative pathological self-assembly process is the formation of amyloid fibrils in patients with 
Alzheimer’s disease. For self-assembly to happen, the concentration of the self-assembly molecules must exceed 
the CAC 11. It could be very difficult to create an environment in which self-assembly peptides exceed CAC in 
the total volume of living cells. However, the concentration of self-assembly peptides could exceed CAC in the 
environment in which they become trapped and are thus unable to be spread outside the organelles.
Mito-FF is more likely to accumulate in cancer cells than in normal cells because cancer cells more fre-
quently have dysfunctional mitochondria and thus have a high negative membrane  potential12,29. Dysfunctional 
mitochondria in cancer cells contribute to the loss of mitochondrial proton gradients to a certain extent, which 
increases the negative potential of  mitochondria11. Therefore, Mito-FF could accumulate in in cancer cells than 
in normal cells, because it has triphenylphosphonium (TPP), the delocalized lipophilic cation that targets better 
to mitochondria of tumor cells with negative membrane potential. Mito-FFs self-assemble in the mitochon-
drial matrix of cancer cells to form fibrous structures, which aggravates mitochondrial dysfunction. As you 
shown in Fig. 6, Mito-FF dramatically increased mitochondrial ROS production above a certain concentration 
(25–50 μM). Excess production of ROS contributes to mitochondrial damage, including mitochondrial DNA 
damage, membrane disruption, and mitochondrial protein damage, all of which ultimately leads to apoptotic 
cell death. Mitochondria have several fundamental functions, including producing the energy required by the 
cell and regulating intracellular oxidative stress by lowering  ROS12,30,31. In this process, mitochondria maintain 
cellular homeostasis by regulating ROS  production32,33. Thus, destruction of mitochondria inevitably leads to 
an increase in ROS and a decrease in antioxidant enzymes.
The pro-apoptotic effect of Mito-FF appears to be more pronounced in the Huh7-S cells than in the Huh7-
R cells. Increased oxidative stress by Mito-FF was more pronounced in the Huh7-S cells than in the Huh7-R 
cells. This difference is thought to be due to the altered characteristics of Huh7-R cells. One of the key metabolic 
alterations in the sorafenib resistant cells is to increase antioxidant  capacity34,35. You et al.36 performed a global 
untargeted metabolomics using sorafenib-resistant cell lines to identify the metabolic alterations relevant to 
the therapeutic resistance. It was found that both cystathionine-β-synthase and cystathionine-gamma-ligase 
were substantially increased in the sorafenib-resistant cells. In addition, the majority of enzymes involved in 
the glutathione synthesis and regeneration were highly expressed in sorafenib-resistant cells Moreover, GPX1, 
the enzyme responsible for scavenging hydrogen peroxide was upregulated in the resistant cells. The sorafenib-
resistant cells exhibited the markedly increased expression of Nrf2, the master transcription factor that regulates 
the expression of various antioxidant  enzymes37.
In this study, the mechanism of action of the anti-tumor effect of Mito-FF was investigated. AKT is involved 
in the regulation of p53 activation: AKT activation leads to the marked suppression of  p5338–40. p53 is critical 
for tumor suppression not only during the acute response to cellular stress, such as DNA damage that is char-
acterized by extensive apoptosis, but also during the quiescent status wherein p53 acts like killing or silencing 
cancer-initiating  cells41. Sorafenib is a protein kinase inhibitor with activity against multiple protein kinases, 
including VEGFR, PDGFR, AKT/ERK and RAF kinases. The inhibition of AKT/ERK activity by sorafenib results 
in activation of p53, which contributes to induction of apoptosis of tumor cells. Sorafenib resistant HCC cells 
exhibit the characteristics of activated the phosphatidylinositol 3-kinase (PI3K)/AKT signaling  pathway42, which 
ultimately limits the induction of apoptosis by the suppression of p53. Our results show that Mito-FF extensively 
increases mitochondrial and intracellular ROS levels. Excess cellular levels of ROS cause damage to proteins, 
nucleic acids, lipids, membranes and organelles, which can directly lead to induction of apoptotic  process43,44. In 
addition, elevated ROS levels suppress the EGFR/PI3K/AKT signaling  pathway45, which in turn activates  p5340, 
ultimately resulting in the acceleration of apoptotic process.
In conclusion, Mito-FF promoted cell apoptosis while inhibiting cell proliferation of Huh7 cells, regardless of 
their sorafenib resistance. To reduce the expression of antioxidant enzymes, Huh7-R cells required more sorafenib 
than Huh7-S cells. However, there was no significant difference in the amount of Mito-FF between Huh7-S and 
Huh7-R cells to reduce the expression of antioxidant enzymes. Mito-FF increased mitochondrial ROS of Huh7 
cells in a concentration-dependent manner even higher than did sorafenib. The results derived from ROS inhibi-
tion suggest that Mito-FF promotes the apoptosis of Huh7-R cells by increasing ROS, which is possibly caused 
Figure 7.  Determination of the action mechanism of Mito-FF in relation with ROS and caspase signaling. (A) 
Cell viability assay of sorafenib-resistant Huh7 cells that were treated with Mito-FF as well as N-acetyl-l-cysteine 
(NAC; ROS inhibitor) [Left] or Z-VAD-fmk (a caspase inhibitor) [Right]. Addition of NAC with Mito-FF-
treated Huh7-R cells significantly increased the cell viability; addition of Z-VAD-fmk did not. (B) Western blot 
analysis showing the expression of PARP (a pro-apoptotic marker) in Huh7-R cells treated either with NAC or 
Z-VAD-fmk. The addition of NAC significantly reduced the expression of PARP in the Mito-FF treated Huh7-R 
cells; the addition of Z-VAD-fmk did not. (C) MitoSOX immunofluorescence of sorafenib-resistant Huh7 cells 
according to the addition of NAC and Z-VAD-fmk, respectively. Percentages of immunofluorescent areas were 
measured using NIH image J (http://image j.nih.gov/ij/downl oad.html) and expressed as relative values to those 
in control cells. (D) DCF-DA immunofluorescence of sorafenib-resistant Huh7 cells according to the addition of 
NAC and Z-VAD-fmk, respectively. Percentages of immunofluorescent areas were measured using NIH image 
J (http://image j.nih.gov/ij/downl oad.html) and expressed as relative values to those in control cells. Values are 
presented as mean ± standard deviation of three independent experiments. *P < 0.05. Abbreviation: DCF-DA, 
2′,7′–dichlorofluorescin diacetate, Huh7-S cell; sorafenib-sensitive Huh7 cell; Huh7-R cell; sorafenib-resistant 
Huh7 cell; Mito-FF; mitochondria-accumulating phenylalanine dipeptide with triphenyl phosphonium; NAC, 
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Figure 8.  Determination of action mechanism of Mito-FF in relation with ROS and p53. (A) 
Immunofluorescent staining of p53 in Huh-S/R cells before and after sorafenib treatment. Following sorafenib 
treatment to Huh7-S cells, there was an increase in the percentage of cells with positive nuclear staining for 
p53; following sorafenib to Huh7-S cells, there was not. (B) Immunofluorescent staining of p53 in Huh-S/R 
cells before and after Mito-FF treatment. There was an increase in the percentage of cells with positive nuclear 
staining for p53following Mito-FF treatment to both Huh7-S/R cells. (C) Possible mechanism of sorafenib and 
Mito-FF in relation with mitochondrial ROS and p53. Sorafenib treatment decreases AKT/ERK in Huh7-S 
cells and thus increases the expression of p53, cumulating in increasing apoptosis. Sorafenib treatment did 
not increase apoptosis in Huh7-R cells—because AKT/ERK was increased in Huh7-R cells and thus p53 was 
decreased. Treating Mito-FF to Huh7-S/R cells, leads to a significant increase of mitochondrial ROS, by way of 
evoking mitochondrial dysfunction due to the accumulation and self-assembly in the mitochondrial matrix, 
resulting in increased expression of p53, which prompts apoptosis.
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by the destruction of the mitochondria of HCC cells. Further investigations are needed to precisely determine 
whether Mito-FF could be an acceptable treatment for patients with sorafenib-resistant HCC.
Material and methods
Chemicals. Sorafenib was purchased from Cayman Chemical (Ann Arbor, MI). NAC and Z-VAD-fmk 
were purchased from Sigma-Aldrich (St. Louis, MO). MitoSOX was obtained from Thermo Fisher Scientific 
(Waltham, MA) and 2′,7′-dichlorodihydrofluorescein diacetate (DCF-DA) was purchased from Thermo Fisher 
Scientific (San Jose, CA).
Cell culture. Huh7 HCC cells were obtained from Korea Cell Line Bank (KCLB, Seoul, Republic of Korea). 
Huh7 cells were maintained in DMEM (Thermo Fisher Scientific, Carlsbad, CA). The medium was supple-
mented with 10% fetal bovine serum (GibcoBRL; Carlsbad, CA) and 1% penicillin–streptomycin (Thermo 
Fisher Scientific) at 37 °C in a humidified atmosphere with 5%  CO2 in an incubator. Passage 35 Huh7-S cells 
were used for the experiment.
Establishment of sorafenib‑resistant HCC cells. To generate sorafenib-resistant cultures, HCC 
Huh7 cells were grown in vitro in the presence of increasing doses of sorafenib (0.5 µM per week) for a total of 
8 months, starting at a sorafenib concentration of 0.5 µmol/L and increasing up to 15 µmol/L. After sorafenib-
resistant HCCs were obtained, they were continuously maintained in DMEM contained with 1 µM sorafenib. 
Passage 51 Huh7-R cells were used for the experiment.
Cell proliferation assay. Proliferation of sorafenib-sensitive/resistant Huh7 cells were evaluated using EZ-
Cytox Cell Proliferation Assay kit (Itsbio, Seoul, Republic of Korea) according to the manufacturer’s instructions.
Western blot analysis. Sorafenib-sensitive/resistant Huh7 cells were lysed using the EzRIPA Lysis kit 
(ATTO Corporation, Tokyo, Japan), and quantified using the Bradford reagent (Bio-Rad, Hercules, CA). Pro-
teins were visualized by western blot analysis using the following primary antibodies (1:1000 dilution) and then 
horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2000 dilution) from Vector Laboratories 
(Burlingame, CA). Specific immune complexes were detected using the Western Blotting Plus Chemilumines-
cence Reagent (Millipore, Bedford, MA). We obtained p53 antibody from Abcam (Cambridge, UK) and other 
antibodies from Cell Signaling Technology (Beverly, MA), including primary antibodies against poly-ADP 
(adenosine diphosphate)-ribose polymerase (PARP), cleaved caspase 3, cleaved caspase 9, B-cell lymphoma-
extra-large (Bcl-xL), BCL2 associated X protein (Bax), phosphorylated extracellular signal-regulated kinase-1 
(p-ERK), superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase, β-actin, and HRP-conjugated 
secondary antibodies.
MitoSOX staining and JC‑1 mitochondrial membrane potential assay. Sorafenib-sensitive/
resistant Huh7 cells were cultured on Lab-Tek chamber slides (Thermo Fisher Scientific). After treatment with 
sorafenib and Mito-FF. respectively, for 24 h, the Huh7 cells were stained with 10 μM MitoSOX or 10 μM DCF-
DA reagent at 37 °C for 10 min and were stained with 5 μM JC-1 for 15 min at 37 °C in the dark. Mitochondrial 
and MMP was observed using the M5000 fluorescence imaging system (EVOS, Invitrogen, CA).
Immunofluorescence. Huh7-S/R cells were cultured on Lab-Tek chamber slides (Thermo Fisher Scien-
tific). The cells were washed three times with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde 
for 30 min, and permeabilized with 0.3% Triton X-100 for 20 min. After blocking with 1% bovine serum albu-
min for 1 h at 25 °C, the slides were incubated with the antibodies against p53 (1:100 dilution, Santa cruz) at 
4 °C overnight. The slides were washed three times with PBS and incubated with Alexa Fluor 594-conjugated 
secondary antibodies (1:500 dilution) for 1 h at 25 °C; the nuclei were counter-stained with DAPI-containing 
VECTASHIELD Mounting Medium (Vector Labs, Burlingame, CA) for 1 min. The samples were observed using 
a fluorescence imaging system (EVOS U5000; Invitrogen, CA).
TUNEL assay. TUNEL analysis was performed for the detection of apoptosis in Huh7-S/R cells using the 
in situ Apoptosis Detection Kit (Takara. Bio, Inc., Japan) following the manufacturer’s instructions. In brief, sam-
ple slides were incubated with 50 μl of TUNEL reaction mixture and TdT labeling reaction mix for 1 h at 37 °C 
in the dark. After being rinsed with PBS three times, the samples were observed using a fluorescence imaging 
system (EVOS U5000; Invitrogen, CA).
Quantification of Cell ROS and apoptosis by flow cytometry. To detect ROS and apoptosis, cells 
were stained with either DCF-DA or Annexin V/PI using the FITC Annexin V apoptosis detection kit (BD 
Biosciences), respectively. After incubation for 15 min in the dark at 25 °C, the cells were analyzed using a BD 
FACSCANTO II cytometer (BD Biosciences).
Quantification of ROS and apoptosis by flow cytometry. To determine intracellular ROS levels and 
the proportion of cells undergoing apoptotic cell death, Huh7 cells were stained with MitoSOX or Annexin V/
propidium iodide (PI), respectively. After incubation for 10 min in the dark at 25 °C, the cells were analyzed 
using an Attune NxT Acoustic focusing cytometer (Thermo Fisher Scientific).
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Statistical analysis. All data were analyzed with SPSS 11.0 software (SPSS Inc., Chicago, IL) and are pre-
sented as mean ± standard deviation. Statistical comparison among groups was determined using Kruskal–Wal-
lis test. Probability values of P < 0.05 were regarded as statistically significant.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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